Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

Exact Sciences Expands Madison, Wisconsin, Campus

01/17/2022
Exact Sciences, a leading global cancer screening and diagnostics company best known for its Cologuard test, is investing an additional $350 million at its campus in Madison, Wisconsin. The project is expected to create more than 1,300 jobs.

The company plans to open a Research and Development Center of Excellence. The new facility will allow Exact Sciences to enhance its research capabilities as the company takes on the world’s deadliest cancers, according to company officials. This includes enhancements to its flagship product, Cologuard, as well as continued work on multi-cancer early detection.

“Since relocating to Wisconsin in 2009, Exact Sciences has grown from a handful of people into a worldwide team focused on eradicating cancer and the suffering it causes,” said Kevin Conroy, Chairman and CEO, Exact Sciences. “Continued investments in our Wisconsin-based people and facilities will accelerate the development of new cancer tests and ensure we continue providing world-class service and critical answers to patients.”

Additional warehouse space is being added to supply the production lab and R&D Center of Excellence. This proposed expansion would consist of ambient storage racking, cold storage and hazardous material storage. In addition, the company is expanding its laboratory space, with a lab featuring new technology and automation to increase overall testing capacity and support Cologuard product development.

“Exact Sciences is an example of a company with deep Wisconsin roots that, with this investment, is committing to its future in our state,” said Missy Hughes, secretary and CEO of the Wisconsin Economic Development Corporation. “As the company has grown to add operations around the world, Exact Sciences could have chosen to expand in other states but chose Wisconsin because of our outstanding, well-educated workers, excellent community infrastructure and support for its research and health care missions.”

The Wisconsin Economic Development Corporation (WEDC) Board of Directors recently authorized increasing the company’s Enterprise Zone tax credits from $9 million to $27.5 million if the company creates at least 1,300 new jobs and invests at least $350 million in capital expenditures by 2025. The previous Enterprise Zone contract required the company to create 758 jobs and invest at least $26.2 million to qualify for $9 million in tax credits; the company has qualified for all the credits by creating more than 2,700 jobs.

WEDC is supporting Exact Sciences’ Wisconsin-based projects with an additional $18.5 million in performance-based Enterprise Zone tax credits, which will be awarded if the company meets the new capital investment and job creation goals by 2025.

“Exact Sciences has already demonstrated an almost unlimited potential to grow,” said Hughes. “The fact that they’re choosing to grow in Wisconsin is testament to the strength of our state’s economy and our strong support for businesses of every size, shape and sector.”

Exact Sciences is best known for its noninvasive colorectal cancer screening test, Cologuard. Approved by the FDA in 2014, the stool DNA test has been used more than 7 million times. Its success enabled Exact Sciences to broaden its aspirations to providing tests and services for people throughout the entire cancer continuum, before, during and after diagnosis. The company plans to add to its west-side Madison campus to support business growth and new products.

Share

Exclusive Research